Skip to main content

Molecular Partners AG (MOLN)

NASDAQ: MOLN · IEX Real-Time Price · USD
19.29 -0.41 (-2.08%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap620.32M
Revenue (ttm)10.62M
Net Income (ttm)-71.32M
Shares Out32.16M
EPS (ttm)-2.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,893
Open19.30
Previous Close19.70
Day's Range19.16 - 19.48
52-Week Range18.00 - 21.33
Beta0.68
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About MOLN

Molecular Partners is a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class...

IndustryBiotechnology
IPO DateJun 16, 2021
CEOPatrick Amstutz
Employees158
Stock ExchangeNASDAQ
Ticker SymbolMOLN
Full Company Profile

Financial Performance

In 2020, MOLN's revenue was 9.34 million, a decrease of -54.16% compared to the previous year's 20.38 million. Losses were -62.76 million, 73.0% more than in 2019.

Financial numbers in millions CHFFinancial Statements

News

Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2...

ZURICH-SCHLIEREN, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs kn...

6 days ago - GlobeNewsWire

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs k...

1 month ago - GlobeNewsWire

Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021

-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3

2 months ago - GlobeNewsWire

AbbVie Returns Eye Drug Candidate To Molecular Partners

AbbVie Inc (NYSE: ABBV) has terminated its license and collaboration agreement with Molecular Partners AG (NASDAQ: MOLN) for abicipar pegol for neovascular age-related macular degeneration (nAMD) and Di...

Other symbols:ABBV
2 months ago - Benzinga

Molecular Partners to Regain Global Rights to Abicipar

ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a...

2 months ago - GlobeNewsWire

Cowen Initiates Coverage On Molecular Partners With Price Target Of $50

Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%. The company and its partner Novart...

3 months ago - Benzinga

Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrat...

ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR

3 months ago - GlobeNewsWire

Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States

Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial pu...

4 months ago - ACCESSWIRE

Molecular Partners IPO Registration Document (S-1)

Molecular Partners AG has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC

EXPLAINED: What is the new Swiss coronavirus drug and how does it work?

While the focus in Switzerland, and elsewhere, has been primarily on vaccines in the past few months, a new medication may also offer hope in the fight against Covid-19. This is what we know about this ...

6 months ago - The Local

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients.

6 months ago - BioSpace